HighTower Advisors
BIOC

HighTower Advisors’s Biocept, Inc. BIOC Stock Holding History

HighTower Advisors’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1
Closed -$21K – 2073
2016
Q1 		$21K Hold
1
– – ﹤0.01% 2011
2015
Q4 		$23K Hold
1
– – ﹤0.01% 1940
2015
Q3 		$45K Buy
+1
New +$62.5K ﹤0.01% 1782

Other funds holding BIOC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MWM
Merriman Wealth Management Seattle, Washington $2.4B AUM 13.66% 1-Year Est. Return

HighTower Advisors's BIOC Position: Q2 2016 in Review

HighTower Advisors sold out of Biocept, Inc. (BIOC) in Q2 2016, closing a stake of 1 share — an estimated $21K sold.

HighTower Advisors first reported a position in BIOC in Q3 2015 and held it in 3 quarters. The position peaked at $45K in Q3 2015. 11 funds tracked by Wall St. Rank hold BIOC as of Q2 2016.

  • HighTower Advisors reported no remaining Biocept, Inc. position as of Q2 2016 after selling out during the quarter.
  • HighTower Advisors sold 1 Biocept, Inc. share in Q2 2016, an estimated $21K.
  • HighTower Advisors first reported a position in Biocept, Inc. in Q3 2015 and held it in 3 quarters.
  • HighTower Advisors's Biocept, Inc. position peaked at $45K in Q3 2015.
  • 11 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2016.

Based on HighTower Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.